GlassScriptPhysician profile
Jill M Warner
NPI 1376824979
$9,852.73
in general payments reported to CMS, 2019-2025
27 companies · $1,835 in 2025
The $1,835 reported for 2025 was more than what 93% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,248 · 2022: $1,919 · 2023: $2,597 · 2024: $2,253 · 2025: $1,835.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,318 · Education: $367.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,318.14 |
| Education | $366.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,752.33 | 2021-2025 | |
| Janssen Biotech, INC. | $878.50 | 2021-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $878.29 | 2021-2025 | Ilumya, Absorica Ld, Winlevi |
| E.R. Squibb & Sons, L.L.C. | $647.60 | 2022-2025 | Sotyktu |
| Dermavant Sciences, INC. | $619.03 | 2022-2024 | Vtama |
| Leo Pharma INC. | $568.88 | 2021-2025 | Adbry, Anzupgo, Spevigo |
| Regeneron Healthcare Solutions, INC. | $539.38 | 2021-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $536.44 | 2021-2025 | Taltz, Ebglyss |
| Incyte Corporation | $505.01 | 2021-2025 | Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $477.42 | 2021-2025 | Siliq, Jublia, Cabtreo |
| Ucb, INC. | $459.34 | 2021-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $393.25 | 2021-2025 | |
| Pfizer INC. | $321.45 | 2021-2025 | |
| Amgen INC. | $285.20 | 2021-2025 | Otezla, Otezla, Enbrel |
| Genzyme Corporation | $238.58 | 2022-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Revance Therapeutics, INC. | $229.55 | 2024-2025 | Daxxify |
| Mallinckrodt Hospital Products INC. | $135.99 | 2025 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.96 | 2023-2025 | Spevigo |
| Organon LLC | $93.79 | 2024-2025 | Vtama |
| Galderma Laboratories, L.P. | $37.24 | 2021-2022 | |
| Arcutis Biotherapeutics, INC. | $30.04 | 2023 | |
| Nobelpharma America, LLC | $20.92 | 2023 | |
| Mayne Pharma Commercial LLC | $20.81 | 2025 | |
| Kyowa Kirin, INC. | $19.81 | 2023 | Poteligeo |
| Helsinn Therapeutics (U.S.), INC. | $19.52 | 2021 | |
| Genentech USA, INC. | $13.91 | 2022 | |
| Myriad Genetic Laboratories, INC. | $11.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Warner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.